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Table S1. Choice of codon degeneracies at each site selected for saturation mutagenesis 
 
Library Randomization 
of amino acids 
Codon 
degeneracy 









Phe, Tyr, Cys, Leu, 
His, Arg, Ile, Asn, Ser, 
Val, Asp, Gly 
Phe, Tyr, Cys, Leu, 
His, Arg, Ile, Asn, Ser, 
Val, Asp, Gly 
144 430 
B Leu143 NNK All twenty amino acids 32 96 
C Fhe505 NNK All twenty amino acids 32 96 
 
Table S2. Primers used for generation of libraries A-C 
 


















Table S3. CHMO mutant Phe432Ile/Thr433Gly/Leu143Met/Phe505Cys as a catalyst in whole-
cell Baeyer-Villiger reactions of ketones 3a-d with formation of lactones 4a-d  
(2 mM, 100 µmol scale, 12h). 
 





3a 4a   76:24   24 16 
3b 4b   20:80   30 46 
3c 4c >99:1 >99   7 
3d 4d   10:90   65 37 
3d 4d
[b]
     4:96 >98   9 
[a] By GC analysis of the crude products, the side-products being the alcohols corresponding to the 







General scheme for preparation of 4-ethylidenecyclohexanone (3a)  
 
 




To a cooled (-70 ºC) solution of ethyltriphenylphosphonium iodide (16.03 g, 38.3 mmol) in 
anhydrous THF (50 mL), n-buthyllithium (15.3 mL, 2.5 M in hexane, 38.3 mmol) was added 
dropwise during 15 min. After 30 min stirring, 1,4-cyclohexanedione monoethylene acetal (5.44 g, 
34.8 mmol) in tetrahydrofuran (50 mL) was added over 20 min and the mixture was then allowed to 
reach r.t. overnight. The solution was then filtered and washed with dichloromethane (3x100 mL), 
the combined fractions concentrated and the resulted yellow oil subjected to column 
chromatography to afford (S1) as a colorless oil (5.21 g, 89%). (Rf=0.38 ethyl acetate/petroleum 
ether=1:15); 
1
H NMR (300 MHz, CDCl3) δ=5.20 (q, 
3
J=6.7 Hz, 1H), 3.96 (s, 4H), 2.24 (m, 4H), 
1.64 (m, 4H), 1.58 (d, 
3
J=6.7 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ=137.36, 116.86, 109.28, 64.43 
(2C), 36.34, 35.43, 33.62, 24.72, 13.06; MS (70 eV, EI): m/z (%): 168 [M]
+
 (64); HRMS (EI) calcd 
for C10H16O2 [M]
+
: 168.1144; found: 168.1139. 
 




An aqueous solution of 20% H2SO4 (5 mL) was added over SiO2 (20 g) in dichloromethane and 
then stirred for 30 min. The acetal (S1) dissolved in dichloromethane (30 mL) was stirred 2 hours at 
r.t., filtered and the organic phase washed with water. After separation and drying, the rota-
evaporated residue was subjected to column chromatography to afford compound 3a as a colorless 
liquid (1.35 g, 78%). (Rf=0.30 ethyl acetate/petroleum ether=1:15); 
1
H NMR (300 MHz, CDCl3) 
δ=5.39 (q, 3J=6.8 Hz, 1H), 2.42 (m, 8H), 1.62 (d, 3J=6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ=212.01, 134.63, 119.48, 41.87, 40.79, 34.22, 25.86, 13.24; MS (70 eV, EI): m/z (%): 124 [M]+ 
(80); HRMS (APCI+) calcd for C8H13O [M+H]
+
: 125.0961; found: 125.0960. 
 












To a cooled (-70 ºC) solution of bromomethyltriphenylphosphonium bromide (7.41 g, 16.9 mmol) 
in anhydrous tetrahydrofuran (40 mL), sodium hexamethyldisilazide (16.9 mL, 1N in 
tetrahydrofuran, 16.9 mmol) was added dropwise. After stirring for 1 h, 1,4-cyclohexanedione 
monoethylene acetal (2.21 g, 14.15 mmol) in tetrahydrofuran (10 mL) was added over 5 min and 
the mixture was allowed to warm at r.t. overnight. Petroleum ether (100 mL) was then added, and 
the resulting suspension was filtered through a short plug of celite. The filtrate was concentrated 
and the resulted yellow oil was subjected to column chromatography to afford compound S2 as 
colorless oil (2.65 g, 80%). (Rf=0.44 ethyl acetate/petroleum ether=1:9); 
1
H NMR (300 MHz, 
CDCl3) δ=5.90 (t, 
4
J=1.2 Hz, 1H), 3.96 (s, 4H), 2.48 (m, 2H), 2.33 (m, 2H), 1.69 (m, 4H); 
13
C NMR 
(75 MHz, CDCl3) δ=142.66, 108.42, 99.07, 64.55 (2C), 35.52, 34.51, 32.16, 27.97; MS (70 eV, EI): 
m/z (%): 232 [M]
+
 (20); HRMS (APCI+) calcd for C9H14BrO2 [M+H]
+
: 233.0172, 235.0152; found: 
233.0170, 235.0149. 
 




To a solution of 8-(bromomethylene)-1,4-dioxaspiro[4.5]decane (S2) (1.70 g, 7.29 mmol) in 
tetrahydrofuran (80 mL), 10% aqueous HCl (40 mL) was added and the mixture stirred for 19 h. To 
the solution ethyl acetate (100 mL) and water (100 mL) were added and the organic phase separated. 
Aqueous phase was twice extracted and then the combined organic extracts were washed with water, 
dried over anhydrous Na2SO4 and concentrated. The residue was subjected to column 
chromatography to afford compound 3b as colorless oil (1.13 g, 82%). (Rf=0.52 ethyl 
acetate/petroleum ether=1:9); 
1
H NMR (300 MHz, CDCl3) δ=6.13 (s, 1H, CHBr), 2.68 (m, 2H), 
2.59 (m, 2H), 2.44 (m, 4H); 
13
C NMR (75 MHz, CDCl3) δ=210.17 (CO), 140.03, 101.86, 40.32, 
39.44, 32.29, 28.72; MS (70 eV, EI): m/z (%): 188, 190 [M]
+
 (72); HRMS (APCI+) calcd for 
C7H10BrO [M+H]
+
: 188.9909, 190.9889; found: 188.9904, 190.9883. 
 




4-(Bromomethylene)cyclohexanone 3b (108 mg, 0.57 mmol) and phenylboronic acid (84 mg, 0.68 
mmol) were added in a 50 mL two necked round bottomed flask. Dioxane/H2O (4:1, 40 mL) was 
further added and solution flushed with nitrogen for 15 minutes, followed by the addition of K2CO3 
(79 mg, 0.57 mmol). After addition of Pd(PPh3)4 (13.2 mg, 0.02% mol) and PPh3 (3 mg, 0.02% 
mol), the solution was heated to 90 ºC and refluxed for 24 hours when GC showed reaction 
completion. The mixture was rota-evaporated and the residue subjected to column chromatography 
to afford compound 3c as a white solid (90 mg, 85%). (Rf=0.36 ethyl acetate/petroleum ether=1:9); 
1
H NMR (300 MHz, CDCl3) δ=7.29-7.14 (m, 5H, HAr), 6.41 (s, 1H), 2.69 (m, 2H), 2.60 (m, 2H), 
2.45 (m, 2H), 2.36 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 211.38, 137.51, 137.32, 128.81, 128.38, 
126.69, 125.78, 77.59, 77.16, 76.74, 41.58, 40.76, 34.85, 27.25; MS (70 eV, EI): m/z (%): 186 [M]
+
 
(100); HRMS (APCI+) calcd for C13H15O [M+H]
+










In a two necked round bottomed flask 4-(bromomethylene)cyclohexanone 3b (301 mg, 1.59 mmol) 
and DIPEA (471 µL, 2.71 mmol) were added to a mixture of dry ethanol and dry tetrahydrofuran 
(2:1, 30 mL) and the solution flushed with argon for 15 minutes. After this time Pd(PPh3)4 (55 mg, 
0.03% mol) and PPh3 (12.5 mg, 0.03% mol) were added and solution flushed for 5 additional 
minutes. A balloon filled with CO was then connected to the solution and a second one was 
attached to the installation equipped with condenser. The mixture was heated at 70 ºC and after 24 
hours GC indicated the total conversion of the starting material. The reaction mixture was rota-
evaporated and the residue charged on a chromatographic column to afford (3d) as a pale yellow 
solid (160 mg, 55%). (Rf=0.41 ethyl acetate/petroleum ether=1:4); 
1
H NMR (300 MHz, CDCl3) δ = 
5.78 (s, 1H), 4.10 (q, 
3





C NMR (75 MHz, CDCl3) δ = 210.21, 166.14, 156.71, 116.19, 59.89, 39.58, 39.00, 33.85, 
26.79, 14.28 ppm; HRMS (EI): calcd for C10H14O3 [M]
-
: 182.0937; found: 182.0943. 
 




Method A. Using the general biotransformation procedure, WT-CHMO and 4-
ethylidenecyclohexanone 3a (0.283 g, 1.5 mmol) afforded (E-4a) as a white solid (0.137 g, 65%); 
E/Z= 98:2. 
 
Method B. (E)-4-bromomethylene-ε-caprolactone (E-4b) (60 mg, 0.29 mmol) and methylboronic 
acid (23 mg, 0.38 mmol) were added in a 50 mL two necked round bottomed flask. Dry 
tetrahydrofuran (25 mL) was further added and solution degassed with argon for 15 minutes, 
followed by the addition of CsF (89 mg, 0.58 mmol). After addition of Pd(PPh3)4 (13.5 mg, 0.04% 
mol) and PPh3 (3 mg, 0.04% mol) the solution was heated to 70 ºC and refluxed for 24 hours when 
TLC showed reaction completion. The solution was rota-evaporated and the residue subjected to 
column chromatography to afford compound E-4a as a white solid (35 mg, 85%). (Rf=0.68 ethyl 
acetate/petroleum ether=1:1); 
1
H NMR (400 MHz, CDCl3) δ=5.24 (q, 
3
J=6.8 Hz, 1H), 4.11 (m, 2H), 
2.54 (m, 2H), 2.39 (m, 2H), 2.33 (m, 2H), 1.53 (d, 
3
J=6.8 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) 
δ=175.56, 136.00, 121.34, 68.77, 39.71, 33.35, 24.00, 12.62; MS (70 eV, EI): m/z (%): 140 [M]+ 
(51); HRMS (APCI+) calcd for C8H13O2 [M+H]
+
: 141.0910; found: 141.0909; trans/cis ≥99:1. 
 




Using the general biotransformation procedure WT-CHMO and 4-bromomethylenecyclohexanone 
(3b) (0.283 g, 1.5 mmol) gave compound E-4b as a white solid (0.189 g, 62%). M.p. 91-93 ºC; 
(Rf=0.40 ethyl acetate/petroleum ether=1:2); 
1
H NMR (300 MHz, CDCl3) δ=6.09 (s, 1H, CHBr), 
4.22 (m, 2H), 2.63 (m, 6H); 
13
C NMR (75 MHz, CDCl3) δ=174.71 (COO), 141.23, 103.96, 67.61, 
38.41, 32.27, 27.39; MS (70 eV, EI): m/z (%): 204, 206 [M]
+
 (2); HRMS (APCI+) calcd for 
C7H10BrO2 [M+H]
+









Using the general biotransformation procedure, mutant-CHMO and bromoketone 3b (0.56 g, 1.5 
mmol) gave compound (Z-4b) after two successive chromatographic columns as a white crystalline 
solid (0.042 g, 7%). (Rf= 0.40 ethyl acetate/petroleum ether=1:2); 
1
H NMR (300 MHz, CDCl3) 
δ=6.14 (s, 1H, CHBr), 4.25 (m, 2H), 2.79 (m, 2H), 2.68 (m, 2H), 2.50 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ=174.61, 141.19, 104.01, 67.09, 34.13, 33.33, 31.78; HRMS (APCI+) calcd for C7H10BrO2 
[M+H]
+
: 204.9858, 206.9838; found: 204.9859, 206.9839.  
 
Diastereoisomers enrichment using column chromatography 
The crude reaction product showed a E/Z ratio of 20:80 according to the GC analysis. First 
purification on column chromatography (ethyl acetate/petroleum ether=1:1) afforded a fraction 
containing the E/Z product (10:90 ratio) according to the GC analysis (126 mg, 21%). A second 
column chromatography (ethyl acetate/petroleum ether=1:2) afforded a fraction containing the E/Z 
product (1:99 ratio) according to the GC analysis (42 mg, 7%).  
 
Diastereoisomers enrichment using HPLC 
A mixture of E/Z lactone (112 mg, E/Z 23:87) dissolved in i-propanol (1.5 mL; final conc. 80.5 
mg/mL) was loaded on a Shimadzu LC-8A HPLC and separated under the conditions mentioned 
bellow: Stationary Phase: LiChrospher Si 100 10 µm; Column 250 x 20 mm BIAX-Column, 95/17; 
Mobile Phase: iso-hexane/iso-propanol=95:5; Flow: 10.0 mL/min; Pressure: 0.2 MPa; Temperature 
308 K; Detection UV, 210 nm, 0.2 mm. After separation, pure diastereoisomer Z (73 mg) was 
collected.  100% Z.  
 




(E)-4-Bromomethylene-ε-caprolactone E-4b (46 mg, 0.22 mmol) and phenylboronic acid (33 mg, 
0.26 mmol) were added in a 50 mL two necked round bottomed flask. Dry tetrahydrofuran (25 mL) 
was further added and the solution degassed with argon for 15 minutes, followed by the addition of 
CsF (68 mg, 0.44 mmol). After addition of Pd(PPh3)4 (10 mg, 0.04% mol) and PPh3 (2 mg, 0.04% 
mol) the solution was heated to 70 ºC and refluxed for 21 hours when GC showed reaction 
completion. The solution was rota-evaporated and the residue subjected to column chromatography 
to afford compound E-4c as a white solid (42 mg, 93%). (Rf=0.44 ethyl acetate/petroleum 
ether=1:2); 
1
H NMR (300 MHz, CDCl3) δ=7.18 (m, 5H, HAr), 6.35 (s, 1H, CHBr), 4.26 (m, 2H), 
2.60 (m, 6H); 
13
C NMR (75 MHz, CDCl3) δ=175.47, 138.56, 136.89, 129.00 (2C), 128.50 (2C), 
127.89, 127.02, 68.59, 40.26, 33.54, 25.47; MS (APCI) m/z: 203,1 [M+H]
+
; HRMS (APCI+) calcd 
for C13H15O2 [M+H]
+
: 203.1067; found: 203.1065; E/Z ≥ 99:1. 
 






Using the general biotransformation procedure ketone 3d (0.144 g, 0.79 mmol) and mutant CHMO 
gave after chromatographic chromatography compound Z-4d as a white solid (0.096 g, 61%). 
Initially the Z/E ratio was (96:4 in the favor of Z). After column chromatography two fractions were 
collected: one containing compound Z-4d (80 mg) (98:2 in the favor of Z) and the other one (16 
mg) containing 87% Z. (Rf= 0.30 ethyl acetate/petroleum ether=1:1); 
1
H NMR (300 MHz, CDCl3) 
δ=5.77 (s, 1H, CHCO2Et), 4.27 (m, 2H), 4.15 (q, 
3
J=7.1 Hz, 2H, CO2CH2CH3), 3.31 (m, 2H), 2.71 
(m, 2H), 2.50 (m, 2H), 1.28 (t, 
3
J=7.1Hz, 3H, CO2CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ=174.60, 
166.11, 156.40, 118.06, 67.34, 60.28, 33.94, 32.68, 32.12, 14.35; HRMS (ES+) calcd for 
C10H14O4Na [M+H]
+
: 221.0784; found: 221.0784; E/Z 2.5:97.5. 
 
 








To a stirred solution of bromolactone E-4b (41 mg, 0.2 mmol) in THF/H2O (8:1, 10 mL) Na2CO3 
(53 mg, 0.5 mmol) was added and then the solution was heated at 70
o
C. The mixture was refluxed 
overnight, allowed to cool to r.t. and then NaOH solution (5 mL) was added followed by the 
addition of ethyl acetate (5 mL). The aqueous phase was separated, washed twice with ethyl acetate, 
then acidified to pH2 and extracted with ethyl acetate twice. The combined organic phases were 
washed with H2O twice, dried over anhydrous Na2SO4 and evaporated to afford (E)-4-
(bromomethylene)-6-hydroxyhexanoic acid (S3) as a colorless oil (37 mg, 83%). (Rf=0.32 ethyl 
acetate); 
1
H NMR (300 MHz, CDCl3) δ=6.54 (broad s, 2H, COOH, OH), 6.03 (s, 1H, CHBr), 3.69 
(t, 
3
J=6.1 Hz, 2H, CH2OH), 2.51-2.34 (m, 6H); 
13
C NMR (75 MHz, CDCl3) δ=178.24 (COOH), 
140.37, 105.36, 60.42, 39.07, 31.48, 28.07; MS (APCI+) m/z: 222.1, 223.0 [M+H]
+
; HRMS (APCI 
-): calcd for C7H10BrO3 [M-H]
-
: 220.9807, 222.9788; found: 220.9819, 222.9798. 
 




(E)-4-Bromomethylene-ε-caprolactone E-4b (44 mg, 0.21 mmol) and DIPEA (37 µL, 0.21 mmol) 
were added in a 25 mL two necked round bottomed flask filled with methanol (25 mL). The mixture 
was then refluxed to 75 
o
C for 2 hours when TLC showed reaction completion. The reaction 
S10 
 
mixture was rota-evaporated and the residue subjected to column chromatography to afford 
compound S4 as colorless oil (42 mg, 88%). (Rf=0.40 ethyl acetate/petroleum ether=1:1); 
1
H NMR 
(300 MHz, CDCl3) δ=6.05 (s, 1H), 3.69 (m, 5H, CH2OH, COOCH3), 2.44 (m, 6H). 
13
C NMR (75 
MHz, CDCl3) δ=173.37 (COOCH3), 140.66, 104.87, 60.28, 51.92, 39.15, 31.54, 28.31. MS 
(APCI+) m/z: 237.2 [M+H]
+
; HRMS: calcd for C8H14BrO3: [M+H]
+
: 237.0121, 239.0101; found: 
237.0120, 239.0099. 
 




(E)-4-Bromomethylene-ε-caprolactone E-4b (40 mg, 0.19 mmol) and phenylboronic acid (29 mg, 
0.23 mmol) were added in a 50 mL two necked round bottomed flask. Dioxane/H2O (4:1, 25 mL) 
was further added and solution degased with nitrogen for 15 minutes, followed by the addition of 
K2CO3 (54 mg, 0.39 mmol). After addition of Pd(PPh3)4 (3 mg, 0.02% mol) the solution was heated 
to 70 ºC and refluxed for 24 hours when GC showed reaction completion. The solution was rota-
evaporated and the residue subjected to column chromatography to afford compound S5 as 
colorless liquid (34 mg, 86%). (Rf=0.60 methanol/ethyl acetate=1:8); 
1
H NMR (300 MHz, DMSO-
d6) δ=7.23 (m, 5H, HAr), 6.24 (s, 1H, CHBr), 3.56 (t, 
3
J=7.0 Hz, 2H, CH2OH), 2.51-2.07 (m, 6H); 
13
C NMR (75 MHz, DMSO-d6) δ=177.87 (COOH), 140.35, 137.72, 128.31 (2C), 128.14 (2C), 
125.98, 125.92, 60.03, 40.10, 34.97, 27.22; MS (ES+) m/z: 243.0 [M+Na]
+
; HRMS (APCI-): calcd 
for C13H15O3 [M-H]
-
: 219.1027; found: 219.1024. 
 




In a two necked round bottomed flask, (E)-4-bromomethylene-ε-caprolactone E-4b (63 mg, 0.30 
mmol) and absolute EtOH (35 mL) were added and the solution flushed with argon for 15 minutes. 
After this time Pd(PPh3)4 (14 mg, 0.05% mol), PPh3 (3 mg, 0.04% mol) and CsF (93 mg, 0.61 
mmol) were added and the solution flushed with argons for 5 additional minutes. A balloon filled 
with CO was then connected to the solution for 10 minutes and a second one was attached to the 
installation equipped with condenser. The mixture was heated at 80 °C and refluxed for 48 hours 
when GC indicated the total conversion of the starting material. The reaction mixture was rota-
evaporated and the residue charged on a chromatographic column to afford E-5 as colorless oil (46 
mg, 61%). (Rf=0.47 ethyl acetate/petroleum ether=1:1); 
1
H NMR (300 MHz, CDCl3) δ=5.76 (s, 1H), 
4.14 (m, 4H), 3.79 (t, 
3





2H), 1.80 (s, 1H), 1.25 (dt, 
3
J=7.1 Hz, 6H); 
13
C NMR (75 MHz, CDCl3) δ=173.11, 165.95, 158.08, 
118.88, 60.71, 60.49, 59.98, 41.48, 33.00, 27.68, 14.38, 14.33; MS (APCI+) m/z: 245.0 [M+H]
+
; 
HRMS (APCI+): calcd for C12H21O5 [M+H]
+














Compound Z-4d (24 mg, 0.12 mmol) was added in absolute ethanol (5 mL) into a 10 mL round 
bottomed flask and the mixture refluxed at 80 °C. The reaction was monitored on GC and after 
completion (aprox. 2 h) the solution was evaporated to dryness to afford compound 6 as a colorless 
liquid. Additionally to the initial mixture DIPEA can be added in catalytic traces to speed up the 
reaction time (24 mg, quant). (Rf=0.37 ethyl acetate/petroleum ether=1:1); 
1
H NMR (300 MHz, 
CDCl3) δ=5.79 (t, 
4
J=1.4 Hz, 1H), 4.37 (t, 
3
J=6.2 Hz, 2H), 4.14 (q, 
3
J=7.1, 2H), 2.56 (m, 4H), 2.41 
(t, 
3




C NMR (75 MHz, CDCl3) δ=172.01, 164.43, 159.48, 
116.17, 66.02, 61.05, 31.41, 31.13, 28.22, 14.33; HRMS (ES+): calcd for C10H14O4Na [M+Na]
+
: 
221.0784; found: 221.0785. 
 
Method B 
In a two necked round bottomed flask bromolactone Z-4b (16 mg, 78 µmol) and CsF (35 mg, 0.234 
mmol) were added to a mixture of dry ethanol and dry tetrahydrofuran (4:1, 15 mL) and the solution 
flushed with argon for 15 minutes. After this time Pd(PPh3)4 (5 mg, 0.05% mol) and PPh3 (1 mg, 
0.05% mol) were added and solution flushed for 5 additional minutes. A balloon filled with CO was 
then connected to the solution and a second one was attached to the installation equipped with 
condenser. The mixture was heated at 80 °C and after 48 hours GC indicated the total conversion of 
the starting material. The reaction mixture was rota-evaporated and the residue charged on a 





Starting from the Criegee intermediate structure containing cyclohexanone (obtained from Polyak et 
al. 2012
2
) the two 4-ethylidene-cyclohexanone-containing Criegee intermediates that would lead to 
the Z- and E-lactone products were built manually. The resulting structures were subjected to the 
QM/MM optimizations using the ChemShell program
3
 and the HDLCopt
4
 optimizer. The 
TURBOMOLE program
5
 was used to obtain the energy and gradients for the QM part using the 
density functional theory (employing the B3LYP functional
6,7,8,9,10,11





 was employed to compute the energy and gradients of the MM part 
represented by the CHARMM22 force field.
14
 The QM region is analogous to the one used in 
Polyak et al, 2012,
22
 containing all atoms from the isoalloxazine ring of C4a-peroxyflavin, the 4-
ethylidene-cyclohexanone, the side chain of Arg329, and the nicotineamide ring and the adjacent 
ribose of NADP
+
. The QM atoms and all the MM atoms within 12 Å of the C4a atom in the 
isoalloxazine ring of FADHOO- were allowed to freely move during the optimization.  
During the two optimizations both Criegee intermediates remained stable and only minor 
conformational changes in the binding site occurred. The two optimized structures differed in the 
QM(B3LYP/TZVP)/CHARMM energy by 2.3 kcal/mol, with the one containing the 4-ethylidene-
cyclohexanone that would lead to formation of the E-lactone product being energetically favored. In 
the other pose (that would lead to the Z-lactone product) in its original non-optimized configuration 
the ethylidene group appears to be too close to the backbone of amino acids 434-435, lining the 
binding pocket. During optimization the 4-ethylidene-cyclohexanone therefore had to perform 
larger displacement from the initial configuration, and, although the Criegee intermediate remained 




MM calculations  
Choosing appropriate randomization sites for iterative saturation mutagenesis (ISM) and 
initial MM analysis  
In order to choose feasible sites for randomization in the process of iterative saturation mutagenesis, 
the X-ray data of the homologous CHMO from Rhodococcus
15
 as a theoretical structural model of 
CHMO from Acinetobacter sp. NCIMB 98 was used as a guide. This model appears to be a good 
starting point to study the observed phenomenon in CHMO. The whole amino acid sequence 
possesses about 75% identity and 85% positives with the CHMO from Acinetobacter (positive 
refers to similar amino acids), and all amino acids within 10 Å from the substrate binding site have 
95% identity and 100% positives. To rationalize the choice of randomization sites for ISM, and to 
unveil the source of E-diasteroselectivity in the case of CHMO wild type (WT) using 
4-ethylidenecyclohexanone (3a), the reactant complex was constructed. The initial structural 
template for the reactant complex was obtained from a previous QM/MM study
2
 using 
cyclohexanone and the X-ray structure of CHMO from Rhodococcus sp. strain HI-31. 
For docking of 4-ethylidenecyclohexanone (3a) into the CHMO binding site, cyclohexanone 
was removed from the reactant complex in the template and 4-ethylidenecyclohexanone was docked 
using the Glide software
16,17,18
. Docking poses were analyzed and most of the aligned substrates 
placed the 4-ethylidene group in an orientation that leads to the E-4a formation (E-binding mode); 
following the corresponding Criegee-intermediate formation, anti-periplanar arrangement and 
σ-bond migration. The best docking result shows an E-binding mode and a docking score of -5.105 
kcal/mol (Fig. S1) and the best obtained pose leading possibly to a Z-configuration product has a 
score of -3.890 kcal/mol. In both cases the key distances in the reactant complex were comparable 
to the distances reported previously for cyclohexanone
2
. For example, the distance between the 
carbonyl oxygen atom of the substrate and the nearest Arg329 NH hydrogen is 1.5 Å (1.735 Å for 
the Z leading pose), and the distance between the C1 carbon of the carbonyl group from the 
substrate and the negatively charge oxygen of the peroxyﬂavin intermediate (FADHOO−) is 3.16 Å 




Figure S1 | Scheme of the reactant complex in the E-selective WT CHMO. The favored reactant 
complex which produces the E-lactone is shown in green together with the riboflavin moiety. The 
formation of Z-lactone derived from the respective reactant complex (methyl group in the 
corresponding ethylidene pointing to the red loop, not shown) is most likely restricted by steric 




In the Polyak et al work
2
, it was shown how the reaction proceeds in the active site, the anti-
periplanar arrangement of C-C-O-O being one of the requirements for smooth cleavage 
(fragmentation) of the Criegee intermediate. The authors affirmed that once the Criegee-
intermediate is formed, there is only one possible σ-bond migration due to the stereoelectronic 
requirement. This implies that the energetically preferred binding mode of cyclohexanone sets the 
stage for all subsequent molecular events. In other words, if a substrate is able to correctly dock into 
the binding site and energetically capable of forming a Criegee-intermediate having an anti-
periplanar C-C-O-O arrangement, then an ester or lactone will be formed. The produced isomer is 
determined previously by the substrate binding mode, which at the same time depends on the 
environmental molecular relation between the substrate and the binding sites (H-bond, hydrophobic 
and electrostatic interactions, steric effects, etc.). According to the docking studies, it can be 
concluded that Z-4a product formation is mainly hampered by steric effects generated from the loop 
431-434, whereas the preferred E-binding mode in the active site is energetically favored and not 
influenced adversely by possible clashes with other residues. The E and Z-configuration in the final 
product is determined by the most favored positional orientation of the 4-ethylidene group in the 
binding site, which is reflected by a better binding score. This orientation could be left or right (E or 
Z respectively) in Fig. S1 (only the E-binding mode is shown). 
This partial theoretical explanation for E-selectivity provided some hints for choosing the 
CAST randomization sites and routing for the ISM experiments. For a limited number of ISM 
experiments, one possible ISM pathway was chosen. This pathway considers the double residue site 
A (positions 434 and 435) and single residue sites B (position 145) as well as C (position 507) 
(Figure S1). The pathway followed the randomization in an A, B and C order. 
Basically, the ISM strategy followed first the generation of permissive mutations to allow the 
binding mode that leads to the corresponding Z-4a formation and afterward mutations that would 
block the binding mode for E-4a formation. This procedure would lead hypothetically to the 
progressive shifting in diasteroselectivity. Although laboratory evolution is rarely predicted in a 
precise way, this rational way to choose the randomization sites for CASTing is expected to 
increase the chances of success.  
The first round of mutation was intended to increase the space in the region of loop 433-436, 
the main identified steric element that favors E-configuration at the expense of the Z-mode. For this 
purpose, positions 434 and 435 were chosen. Later on, residues presumably capable of blocking the 
E-binding mode were proposed, and residues 145 and 507 appeared to be at right position and 
distance for this goal (Fig. S1). At this point, the possible optimal mutations can be expected to 
have large enough side chains  to disfavor the 4-ethylidene orientation that results in a E-4a 
formation, but not too large to block the alternative substrate alignment that generates the Z-4a 
lactone. 
 
Analysis of the Criegee-intermediates leading to E- or Z-lactone formation 
The two possible Criegee-intermediates producing either the E or Z configurated lactone were 
analyzed (Fig. S2). To build this intermediate, the ethylidene group at position 4 in the Criegee 
intermediate of cyclohexanone previously optimized at a QM(B3LYP/TZVP)/CHARMM level
2
 
was added manually.  
Energy and MD minimization were applied to adjust the new position of residues in the active 
site. Because the stereo-electronic requirement for the Criegee intermediate to proceed in the BV 
reaction comprises an anti-periplanar rearrangement with the FADO:OX3-OX3’-CYHN:C1-C2 
dihedral angle being close to 180º (consult reference 2), our MD simulation for the two possible 
Criegee-intermediates were performed constraining such dihedral angle close to 180º. 10 ns of 
productive simulation was obtained using the Desmond program and OPLS-AA force field
19,20,21
. 
The MD simulations used the SPC water solvent system
22,23
 including a concentration of 150 mM 
NaCl. Partial atomic charges of the 4-ethylidenecyclohexanone in the Criegee-intermediate were 
calculated using the Jaguar application
18
 (electrostatic potential fitting) to improve the 
representation of molecular electrostatic potential. These parameters were included in the force field 
used for the MD simulations. Long-range electrostatic interactions using Particle Mesh Ewald 
S15 
 
(PME) and van der Waals interactions were computed with a real space contributions truncated at 
9Å. Bond lengths to hydrogens were constrained by using the SHAKE algorithm. A RESPA 
integrator was used with time steps set to 2 fs for bonded and short-range nonbonded interactions, 
and 6 fs for long-range electrostatic interactions. Prior to every dynamic simulation, the solvated 
systems were relaxed into a local energy minimum using 500 steps of a hybrid method of steepest 
descent minimization and a limited-memory Broyden-Fletcher-Goldfarb-Shanno (L-BFGS) 
minimization. Additionally before simulation, the model systems were relaxed through a series of 
minimization and short dynamic simulations (NPT ensemble using a Berendsen thermostat and 
barostat) equilibrating the system at 300 K and 1 atm. Finally, production simulations were 
performed for every solvated system during 10 ns, coupling the system using NPT simulation, 
maintaining 1 atm at 300 K with a Martyna–Tobias–Klein barostat (relaxation time of 2 ps) and a 
Nose–Hoover thermostat (relaxation time of 0.5 ps). The difference in the total potential energy in 
the whole enzyme/Criegee-intermediate complex between the E and Z configuration using the opls-
2005 force field was 1883 KJ/mol (450 kcal/mol), favoring the E configuration. 
The corresponding Criegee-intermediate for the Z formation is less energetically favored 
compared to the E configuration. This effect and the preferred binding mode is explained basically 
by the restricted space in the active site, where the substrate orientation is sterically arranged to a 
reactant complex which would consecutively produce the corresponding E product. 
After manually forcing the Z arrangement into the Criegee-intermediate, and after minimizing 
the structure, it becomes clear  that a notable global structural arrangement is necessary to harbor 
such intermediates into the active site compared to the E pose, especially  at the loop 433-436, 
which would explain the big differences in terms of potential energy. RMSD values between the 
template Criegee-intermediate (QM/MM optimized intermediate
2
) and the corresponding E and Z 
intermediate including only the residues within 7 Å from the substrate proved to be 1 Å larger for 
the Z configuration, reflecting the major protein rearrangement in the Z case.  
As already mentioned, a QM/MM study of CHMO-catalyzed desymmetrization of 
4-methylcyclohexanone sheds light on the origin of this type of stereoselectivity, the energetic 
difference between this substrate with methyl in the equatorial versus axial orientation determining 




In the present case of substrate 3a, the molecule is more flexible 
and the equatorial/axial issue is not relevant. Nevertheless, the two possible orientations of the 4-
ethylidene in the substrate direct the final diasteroselectivity. The E and Z configuration in the final 
product is determined by the most favored positional orientation of the 4-ethylidene group in the 
binding site, which is reflected by a better binding score and more stable Criegee-intermediate. This 
orientation could be left or right in Fig. S2 (E and Z respectively). Thus, the present MM analysis 






Figure S2 | Scheme of the Criegee-intermediate in the E-selective WT CHMO. The favored 
Criegee-intermediate which produces the E-lactone is shown in green together with the riboflavin 
moiety. The intermediate going to the Z-lactone is represented with a black methyl group in the 
corresponding ethylidene. The formation of the Z-isomer is clearly restricted by the amino acids 
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H NMR spectra of compounds E-4b and Z-4b (300 MHz,CDCl3) 
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COSY spectrum of compound Z-4b (CDCl3)  
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E-4a and Z-4a 15 m DB-Wax, inner diameter of 0.25 mm; film thickness of 0.15 μm, pressure: 0.4 
bar H2; injector: 230 °C; oven: temperature gradient: 80–260 °C with 6 °C/min from 
260 °C 5 min isothermic, FID detector: 350 °C. 
14.51 cis 
14.71 trans 
E-4b and Z-4b 15 m DB-Wax, inner diameter of 0.25 mm; film thickness of 0.15 μm, pressure: 0.4 
bar H2; injector: 230 °C; oven: temperature gradient: 80–260 °C with 6 °C/min from 
260 °C 5 min isothermic, FID detector: 350 °C. 
18.22 cis 
18.55 trans 
E-4c 15 m DB-Wax, inner diameter of 0.25 mm; film thickness of 0.15 μm, pressure: 0.4 
bar H2; injector: 230 °C; oven: temperature gradient: 80–260 °C with 6 °C/min from 
260 °C 5 min isothermic, FID detector: 350 °C. 
21.54 trans 
E-4d and Z-4d 15 m DB-Wax, inner diameter of 0.25 mm; film thickness of 0.15 μm, pressure: 0.4 
bar H2; injector: 230 °C; oven: temperature gradient: 80–260 °C with 6 °C/min from 





Preparative HPLC for compound 4b 











4b 100 mm Interchim Strategy 2.2 
Si, 4.6 mm i. D.  
n-Heptane/iso-propanol=90:10;  
flow: 1.0 mL/min, 7.6 MPa, 308 
K; UV, 210 nm. 
3.54 (cis), 
4.41 (trans) 
Stationary phase: LiChrospher 
Si100, 10 µm, 20 mm i. D.; 
column: 250 x 20 mm BIAX-
Säule, 95/17; iso-Hexane/ iso-
Propanol=95:5;  
flow: 10.0 mL/min, 0.2 MPa, 308 
K; Detection UV, 210 nm. 







Preparation of (E)-4-ethylidene-ε-caprolactone (E-4a) resulting from biocatalytic Baeyer-










Preparation of (Z)-4-ethylidene-ε-caprolactone (Z-4a) resulting from biocatalytic Baeyer-








Preparation of (E)-4-bromomethylene-ε-caprolactone (E-4b) resulting from biocatalytic 








Preparation of (Z)-4-bromomethylene-ε-caprolactone (Z-4b) resulting from biocatalytic 










Mixture of (E)-4-bromomethylene-ε-caprolactone (E-4b) and (Z)-4-bromomethylene-ε-
caprolactone (Z-4b) (87:13 trans/cis) 
 
 
Sample resulted from the first column chromatography of the biocatalytic Baeyer-Villiger reaction 








































Figure S3 | The molecular structure of E-4b. Atomic displacement ellipsoids are shown at the 
50% probability level 
 
 
Crystal Data for E-4b: [C7 H9 Br O2], Mr = 205.05  g · mol
-1
, colourless plate, crystal size 0.02 x 
0.18 x 0.22 mm
3
, monoclinic, space group P21/c, a =  12.764(3) Å, b = 8.6044(6) Å, c = 7.2488(7) 
Å,  = 104.256(10)°, V = 771.6(2) Å3, T = 100 K, Z = 4, Dcalc = 1.765  g·cm
3
, Mo-K radiation,  = 
0.71073 Å,  = 5.262 mm-1, Gaussian absorption correction (Tmin = 0.42296, Tmax = 0.90081), 
minimum and maximum estimated transmissions from the multi-scan scaling: 0.3985 and 0.9423 
(SADABS), Bruker AXS Enraf-Nonius KappaCCD diffractometer, 2.88 <  < 33.21°, 24703 
measured reflections, 2946 independent reflections (Rint = 0.069), 2454 reflections with I > 2(I). 




 to R1 = 
0.0352 [I > 2(I)], wR2 = 0.0941, 91 parameters (G. M. Sheldrick, Acta Cryst. 2008, A64, 112-122). 
S = 1.153, residual electron density +1.38 / -0.13 e Å
-3
. CCDC 880686. 
 
Data were collected to a resolution of 0.65 Å with an average redundancy of greater than 8 (see 
statistics, below). One reflection was lost, owing to the shadow cast by the beamstop. Although the 
face-indexed absorption correction was undertaken with as much care as possible, the observed 
negative residual electron density of -0.43 eÅ
-3
, 0.82 Å from O2, which is smaller than the negative 
residual electron density next to Br, may be due to the difficulty of accurately correcting for the 
effects of X-ray absorption for a plate composed of a substance with such a high linear absorption 





INTENSITY STATISTICS FOR DATASET  
 
Resolution  #Data #Theory %Complete Redundancy Mean I Mean I/s R(int) Rsigma 
 
 Inf - 1.80     158    162     97.5    13.04     121.7   38.04  0.0736  0.0236 
1.80 - 1.42     158    158    100.0    11.45      77.3   36.48  0.0618  0.0224 
1.42 - 1.24     161    162     99.4    11.15      49.8   35.55  0.0587  0.0221 
1.24 - 1.12     171    171    100.0    10.67      47.6   35.78  0.0527  0.0222 
1.12 - 1.03     175    175    100.0    10.33      28.1   28.79  0.0599  0.0246 
1.03 - 0.97     166    166    100.0    10.01      26.2   27.66  0.0633  0.0259 
0.97 - 0.92     164    164    100.0     9.68      23.9   28.91  0.0609  0.0260 
0.92 - 0.88     165    165    100.0     8.76      19.4   24.96  0.0645  0.0309 
0.88 - 0.84     202    202    100.0     8.50      13.8   19.88  0.0704  0.0366 
0.84 - 0.81     157    157    100.0     8.18      14.8   19.78  0.0745  0.0372 
0.81 - 0.78     207    207    100.0     7.42      11.1   16.20  0.0822  0.0448 
0.78 - 0.75     241    241    100.0     6.70       9.2   13.78  0.0924  0.0553 
0.75 - 0.73     175    175    100.0     6.50       8.4   12.72  0.1068  0.0616 
0.73 - 0.71     198    198    100.0     5.95       7.0   11.14  0.1181  0.0741 
0.71 - 0.69     235    235    100.0     5.49       6.0    9.31  0.1324  0.0879 
0.69 - 0.67     233    234     99.6     4.74       5.0    7.21  0.1520  0.1132 
0.67 - 0.65     151    158     95.6     3.72       3.5    4.88  0.1967  0.1684 
------------------------------------------------------------------------------ 
0.75 - 0.65    1077   1085     99.3     5.41       6.1    9.36  0.1250  0.0876 
 Inf - 0.65    3117   3130     99.6     8.15      25.5   20.83  0.0683  0.0311 
 
Merged [A],  lowest resolution =  7.06 Angstroms,    636 outliers downweighted 
------------------------------------------------------------------------------- 
 
The highest peak in the residual electron density map is  1.38  at  0.6381  0.3487  0.2177,  0.87 Å 




Table S4. Atomic coordinates and equivalent isotropic displacement parameters (Å2). 
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
_________________________________________________________________________ 
 x y z Ueq 
_________________________________________________________________________ 
C(1) 0.7161(2) 0.2934(2) 0.2370(3) 0.016(1) 
C(2) 0.7559(2) 0.1500(2) 0.2754(3) 0.013(1) 
C(3) 0.8774(2) 0.1311(2) 0.3245(3) 0.018(1) 
C(4) 0.9179(2) 0.0218(2) 0.1918(3) 0.017(1) 
C(5) 0.8136(2) -0.2126(2) 0.2096(3) 0.016(1) 
C(6) 0.7104(2) -0.1213(2) 0.1346(3) 0.017(1) 
C(7) 0.6893(2) 0.0062(2) 0.2722(3) 0.016(1) 
Br(1) 0.5677(1) 0.3461(1) 0.1767(1) 0.023(1) 
O(1) 0.9099(1) -0.1410(2) 0.2398(2) 0.018(1) 








C(1)-C(2) 1.338(3) C(1)-Br(1) 1.891(2)
C(2)-C(7) 1.499(3) C(2)-C(3) 1.512(3)
C(3)-C(4) 1.524(3) C(4)-O(1) 1.453(2)
C(5)-O(2) 1.217(2) C(5)-O(1) 1.344(2)
C(5)-C(6) 1.515(3) C(6)-C(7) 1.550(3) 
 
C(2)-C(1)-Br(1)     125.20(16) C(1)-C(2)-C(7)     125.02(18) C(1)-C(2)-
C(3)      117.57(17)  
C(7)-C(2)-C(3)      117.41(15) C(2)-C(3)-C(4)     113.92(16) O(1)-C(4)-
C(3)      112.89(16)  
O(2)-C(5)-O(1)     117.29(19) O(2)-C(5)-C(6)     122.65(19) O(1)-C(5)-
C(6)      120.05(16)  
C(5)-C(6)-C(7)      114.16(17) C(2)-C(7)-C(6)     113.99(16) C(5)-O(1)-






Table S6. Anisotropic displacement parameters (Å2).  
The anisotropic displacement factor exponent takes the form:  
 -22[ h2a*2U11 + ... + 2 h k a* b* U12 ]. 
________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
________________________________________________________________________ 
C(1) 0.020(1)  0.012(1) 0.016(1)  0.000(1) 0.004(1)  0.002(1) 
C(2) 0.015(1)  0.011(1) 0.014(1)  -0.001(1) 0.005(1)  0.000(1) 
C(3) 0.016(1)  0.014(1) 0.022(1)  -0.004(1) 0.003(1)  -0.001(1) 
C(4) 0.017(1)  0.012(1) 0.023(1)  0.001(1) 0.007(1)  -0.001(1) 
C(5) 0.020(1)  0.010(1) 0.018(1)  -0.001(1) 0.006(1)  0.001(1) 
C(6) 0.015(1)  0.013(1) 0.021(1)  -0.002(1) 0.004(1)  -0.001(1) 
C(7) 0.017(1)  0.011(1) 0.023(1)  0.002(1) 0.009(1)  0.000(1) 
Br(1) 0.024(1)  0.020(1) 0.024(1)  0.003(1) 0.006(1)  0.010(1) 
O(1) 0.016(1)  0.013(1) 0.026(1)  0.001(1) 0.005(1)  0.002(1) 
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